|
|
... -molecule inhibitor nutlin-3 may be a viable treatment option for neuroblastoma patients with wild-type p53 activity, according to a new study published online November 10 in the Journal of the National Cancer ... in Belgium, and colleagues evaluated the antitumor efficacy of nutlin-3, a potent and selective antagonist of the p53-MDM2 interaction.Original post by Allergy News From Medical News Today
|
|
|
... per group) and were used to evaluate effects on tumor growth, p53 pathway activity, and metastatic tumor burden. ... -NB-3rDOX20 cells, as evidenced by increased expression of p53 target genes, G1 cell cycle arrest, ... to 1311 mm3, P < .001), p53 pathway activation, and reduction in the extent of metastatic ... -3.
Conclusions
Nutlin-3 activates the p53 pathway and suppresses tumor growth in this model ...
|
|
|
... -negative effects over the remaining wild-type protein, several p53 mutants can gain novel oncogenic functions (gain-of- ... cancer development and progression. In human endometrial cancer, p53 mutation is more often associated with aggressive nonendometrioid cancer. However, it was unknown if ... These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function ...
|
|
|
... virus infection. We analyzed whether CK1 regulates p53 protein stability in unstressed conditions. Depletion ... CK1 using the kinase inhibitor (D4476) activated p53 and destabilized E2F-1, indicating that steady ... middot;CK1 complex is both a negative regulator of p53 and a positive regulator of E2F-1 in undamaged ... p53-independent apoptosis by D4476 suggested a critical role for the MDM2·CK1 complex ...
|
|
|
... report, we characterized TFAM and its interaction with tumor suppressor p53 using various biophysical methods. DNA-free TFAM is a thermally ... ± 0.19 µM. The C-terminal regulatory domain of p53 provides a secondary binding site for TFAM. The TFAM–p53-binding ... p53 binds preferentially to distorted DNA, the TFAM–p53 interaction is implicated in DNA damage and repair. In addition ...
|
|
|
... Reviews Molecular Cell Biology present a free poster on the rise of p53, by Bert Vogelstein and Carol Prives. "In 1979 the ... characterized as a tumour suppressor, which led to a steep rise in p53 research. We now know that the protein encoded by TP53 — one of the most ... the past 30 years that have led to our current understanding of p53 biology and complements the Nature Reviews Cancer Focus on ...
|
|
|
... research community: "more than half of all human cancers have mutations that disable a protein called p53. As a critical anti-cancer watchdog, p53 masterminds several cancer-fighting operations within cells. When cells lose p53, tumors grow aggressively and often cannot be treated. ... were abruptly shut down, and the tumors even shrank in size ...
|
|
|
... p53 has become the focus of intensive cancer-based research in laboratories around the world. The p53 protein mediates critical cellular functions including the response to genotoxic stress, ... mutated in a large proportion of human cancers. These observations led many to speculate that targeting the p53 pathway would result in the development of successful anti-cancer treatments. In spite of this, ...
|
|
|
Anticancer DNA intercalators cause p53-dependent mtDNA nucleoid re-modellingAnticancer DNA intercalators cause p53dependent mitochondrial DNA nucleoid remodellingN Ashley and J PoultonOncogene 28 (44), 3880-91 (17 Aug 2009)Posted by katsmiyake to Drug on Mon Nov 09 2009 at 08:23 UTC | info | related
|
|
|
Transformation to acute myeloid leukemia may occur in patients with myelodysplastic syndrome with isolated del(5q) treated with lenalidomide, particularly in those without a cytogenetic response. In this study, the authors performed molecular investigations in a patient with classical 5q- syndrome with complete erythroid and partial cytogenetic response to lenalidomide, who later developed high- ...
|
|
|
... we acquired a mouse with a genetic predisposition for cancer-the p53 knockout mouse from Alan Harris at the Walter ... genotype we saw that, as expected, all of these mice lacked both copies of p53. Interestingly, mice that lacked both copies of perforin ... excited us, but we anticipated that the mice missing only one p53 allele would be even more revealing since the cancer development in these mice ...
|
|
|
... times before, most recently here, where new research about the anti-cancer properties of p53 is described.) Such proteins are normally subject to regulation themselves, and they become available and active only when needed, such as ... are weakened or sidelined.
As it turns out, according to recent research, among the ways that p53 promotes apoptosis is by direct interference with NF-κB' ...
|
|
|
... centres on the transcription factor and tumour suppressor, p53. We aimed to explain the behaviour of as high a proportion ... RNFB19B is activated by a slower transcription factor (p53) but tends to track its movement more closely because of a relatively high transcript ... improves on existing methodsAlthough no previous knowledge of p53 targets was used in the modelling, GWTM was successful in identifying ...
|
|
|
... characterization of serous tubal intraepithelial carcinoma (STIC) and of the p53 signature suggested that HG-PSC may follow a ... progression. Immunoreactivity for HMGA2 may lead to a novel, useful biomarker to complement p53 in the detection of early-stage serous carcinoma. (#19898227#)
References
HMGA2: A Potential Biomarker Complement to P53 for Detection of Early-stage High-grade Papillary ...
|
|
|
... of Georgia, estrogen can inhibit stroke damage by inactivating p53 (a tumor-suppressing protein) that is known to inhibit many forms of cancer ... that the research suggests that estrogen is capable of suppressing p53 after stroke and thus inhibit the damage.
From Sciencedaily.com:
Ms. Raz found that estrogen can chemically alter p53 and attenuate the cascade, thus leading to reduced stroke damage.
...
|
|
Related Tags
|
